Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-38 in Pediatric High Grade Gliomas
NCT00074334Phase 2Terminated
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- May 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nalmefene in high-grade glioma (HGG), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Maximum safe volume rate of TP-38 infused through three catheters or through two catheters, Maximum tolerated infusion concentration of TP-38 infused through three catheters or through two catheters and 2 more. Started May 2004; status: terminated.
02
Drugs
nalmefene
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00074334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074334.